{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:13:35Z","timestamp":1791231215094,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01371-0","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T15:45:19Z","timestamp":1761320719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hypoalbuminemia: a new risk factor for progression in patients with monoclonal gammopathy of uncertain significance"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0981-4882","authenticated-orcid":false,"given":"Elena","family":"Alejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5493-6707","authenticated-orcid":false,"given":"Ver\u00f3nica","family":"Gonz\u00e1lez-Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Bl\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Puertas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Agull\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Rey-B\u00faa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma C.","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7535-3861","authenticated-orcid":false,"given":"Noemi","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"1371_CR1","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5.","journal-title":"Lancet Oncol"},{"key":"1371_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.blre.2007.01.002","volume":"21","author":"SV Rajkumar","year":"2007","unstructured":"Rajkumar SV, Lacy MQ, Kyle RA. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Rev. 2007;21:255\u201365. https:\/\/doi.org\/10.1016\/j.blre.2007.01.002.","journal-title":"Blood Rev"},{"key":"1371_CR3","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. New Engl J Med. 2006;354:1362\u20139. https:\/\/doi.org\/10.1056\/NEJMoa054494.","journal-title":"New Engl J Med"},{"key":"1371_CR4","doi-asserted-by":"publisher","first-page":"933","DOI":"10.4065\/mcp.2010.0337","volume":"85","author":"RK Wadhera","year":"2010","unstructured":"Wadhera RK, Rajkumar SV. Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin Proc. 2010;85:933\u201342. https:\/\/doi.org\/10.4065\/mcp.2010.0337.","journal-title":"Mayo Clin Proc"},{"key":"1371_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00480-w","volume":"11","author":"S R\u00f6gnvaldsson","year":"2021","unstructured":"R\u00f6gnvaldsson S, Love TJ, Thorsteinsdottir S, Reed ER, \u00d3skarsson J\u00de, P\u00e9tursd\u00f3ttir \u00cd, et al. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 2021;11:1\u201313. https:\/\/doi.org\/10.1038\/s41408-021-00480-w.","journal-title":"Blood Cancer J"},{"key":"1371_CR6","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","volume":"64","author":"RA Kyle","year":"1978","unstructured":"Kyle RA. Monoclonal gammopathy of undetermined significance. Am J Med. 1978;64:814\u201326. https:\/\/doi.org\/10.1016\/0002-9343(78)90522-3.","journal-title":"Am J Med"},{"key":"1371_CR7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.4065\/79.7.859","volume":"79","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original mayo clinic series 25 years later. Mayo Clin Proc. 2004;79:859\u201366. https:\/\/doi.org\/10.4065\/79.7.859.","journal-title":"Mayo Clin Proc"},{"key":"1371_CR8","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","volume":"128","author":"MV Dhodapkar","year":"2016","unstructured":"Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood. 2016;128:2599\u2013606. https:\/\/doi.org\/10.1182\/blood-2016-09-692954.","journal-title":"Blood"},{"key":"1371_CR9","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113:5412\u20137. https:\/\/doi.org\/10.1182\/blood-2008-12-194241.","journal-title":"Blood"},{"key":"1371_CR10","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/j.1365-2141.2007.06873.x","volume":"139","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol. 2007;139:730\u201343. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06873.x.","journal-title":"Br J Haematol"},{"key":"1371_CR11","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.mayocp.2019.12.033","volume":"95","author":"A Ravindran","year":"2020","unstructured":"Ravindran A, Lackore KA, Glasgow AE, Drake MT, Hobbs MA, Kourelis T, et al. Monoclonal gammopathy of undetermined significance: indications for prediagnostic testing, subsequent diagnoses, and follow-up practice at Mayo Clinic. Mayo Clin Proc. 2020;95:944\u201354. https:\/\/doi.org\/10.1016\/j.mayocp.2019.12.033.","journal-title":"Mayo Clin Proc"},{"key":"1371_CR12","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.1016\/j.clml.2024.12.006","volume":"25","author":"Y Li","year":"2025","unstructured":"Li Y, Hsu SH, Wang R, Theprungsirikul P, Neparidze N, Chang SH, et al. Associations between patient characteristics and progression to multiple myeloma among patients with monoclonal gammopathy of undetermined significance: a systematic review. Clin Lymphoma Myeloma Leuk. 2025;25:e222\u201331. https:\/\/doi.org\/10.1016\/j.clml.2024.12.006.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1371_CR13","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812\u20137. https:\/\/doi.org\/10.1182\/blood-2005-03-1038.","journal-title":"Blood"},{"key":"1371_CR14","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1200\/JCO.22.01916","volume":"41","author":"L Burgos","year":"2023","unstructured":"Burgos L, Tamariz-Amador LE, Puig N, Cedena MT, Guerrero C, Jel\u00ednek T, et al. Definition and clinical significance of the monoclonal gammopathy of undetermined significance\u2013like phenotype in patients with monoclonal gammopathies. JCO. 2023;41:3019\u201331. https:\/\/doi.org\/10.1200\/JCO.22.01916.","journal-title":"JCO"},{"key":"1371_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2023-188547","volume":"142","author":"T Einarsson Long","year":"2023","unstructured":"Einarsson Long T, R\u00f6gnvaldsson S, Thorsteinsdottir S, Sverrisdottir I, Eythorsson E, Indridason O, et al. Revised definition of free light chains in serum and light chain monoclonal gammopathy of undetermined significance: results of the ISTOPMM study. Blood. 2023;142:535 https:\/\/doi.org\/10.1182\/blood-2023-188547.","journal-title":"Blood"},{"key":"1371_CR16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s11914-018-0479-z","volume":"16","author":"B G\u00e1mez","year":"2018","unstructured":"G\u00e1mez B, Edwards CM. Contributions of the bone microenvironment to monoclonal gammopathy of undetermined significance pathogenesis. Curr Osteoporos Rep. 2018;16:635\u201341. https:\/\/doi.org\/10.1007\/s11914-018-0479-z.","journal-title":"Curr Osteoporos Rep"},{"key":"1371_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1182\/blood-2023-178534","volume":"142","author":"I Cenzano","year":"2023","unstructured":"Cenzano I, Cocera M, Bantan A, Larrayoz M, Vilas-Zornoza A, San-Martin P, et al. Comprehensive characterization of the bone marrow microenvironment transcriptional remodeling in the progression from MGUS to smoldering and multiple Myeloma. Blood. 2023;142:88 https:\/\/doi.org\/10.1182\/blood-2023-178534.","journal-title":"Blood"},{"key":"1371_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2025.104268","volume":"54","author":"C Saade","year":"2025","unstructured":"Saade C, Ghobrial IM. Updates on mechanisms of disease progression in precursor myeloma: Monoclonal gammopathy of undermined significance and smoldering myeloma. La Presse M\u00e9d. 2025;54:104268. https:\/\/doi.org\/10.1016\/j.lpm.2025.104268.","journal-title":"La Presse M\u00e9d"},{"key":"1371_CR19","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garc\u00eda-S\u00e1nchez O, B\u00f6ttcher S, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094\u2013103. https:\/\/doi.org\/10.1038\/leu.2017.29.","journal-title":"Leukemia"},{"key":"1371_CR20","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","volume":"97","author":"FM Ross","year":"2012","unstructured":"Ross FM, Avet-Loiseau H, Ameye G, Gutierrez NC, Liebisch P, O\u2019Connor S, et al. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012;97:1272\u20137. https:\/\/doi.org\/10.3324\/haematol.2011.056176.","journal-title":"Haematologica"},{"key":"1371_CR21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564\u20139. https:\/\/doi.org\/10.1056\/NEJMoa01133202.","journal-title":"N Engl J Med"},{"key":"1371_CR22","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.beha.2005.01.025","volume":"18","author":"RA Kyle","year":"2005","unstructured":"Kyle RA, Vincent Rajkumar S. Monoclonal gammopathies of undetermined significance. Best Pract Res Clin Haematol. 2005;18:689\u2013707. https:\/\/doi.org\/10.1016\/j.beha.2005.01.025.","journal-title":"Best Pract Res Clin Haematol"},{"key":"1371_CR23","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3324\/haematol.2009.013961","volume":"94","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Kumar S. The significance of monoclonal gammopathy of undetermined significance. Haematologica. 2009;94:1641\u20134. https:\/\/doi.org\/10.3324\/haematol.2009.013961.","journal-title":"Haematologica"},{"key":"1371_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1182\/blood.2024025415","volume":"145","author":"A Visram","year":"2025","unstructured":"Visram A, Larson D, Norman A, Dispenzieri A, Murray D, Kyle R, et al. Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection. Blood. 2025;145:325\u201333. https:\/\/doi.org\/10.1182\/blood.2024025415.","journal-title":"Blood"},{"key":"1371_CR25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378:241\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1709974.","journal-title":"N Engl J Med"},{"key":"1371_CR26","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1200\/JCO.2002.20.6.1625","volume":"20","author":"C Cesana","year":"2002","unstructured":"Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple Myeloma. JCO. 2002;20:1625\u201334. https:\/\/doi.org\/10.1200\/JCO.2002.20.6.1625.","journal-title":"JCO"},{"key":"1371_CR27","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","volume":"110","author":"E P\u00e9rez-Persona","year":"2007","unstructured":"P\u00e9rez-Persona E, Vidriales MB, Mateo G, Garc\u00eda-Sanz R, Mateos MV, De Coca AG, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586\u201392. https:\/\/doi.org\/10.1182\/blood-2007-05-088443.","journal-title":"Blood"},{"key":"1371_CR28","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","volume":"24","author":"RA Kyle","year":"2010","unstructured":"Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121\u20137. https:\/\/doi.org\/10.1038\/leu.2010.60.","journal-title":"Leukemia"},{"key":"1371_CR29","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1182\/blood-2010-04-277566","volume":"116","author":"G Bianchi","year":"2010","unstructured":"Bianchi G, Kyle RA, Colby CL, Larson DR, Kumar S, Katzmann JA, et al. Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood. 2010;116:2019\u201325. https:\/\/doi.org\/10.1182\/blood-2010-04-277566.","journal-title":"Blood"},{"key":"1371_CR30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1365-2141.2010.08207.x","volume":"150","author":"JR Berenson","year":"2010","unstructured":"Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, et al. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol. 2010;150:28\u201338. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08207.x.","journal-title":"Br J Haematol"},{"key":"1371_CR31","first-page":"578","volume":"25","author":"RA Kyle","year":"2011","unstructured":"Kyle RA, Rajkumar SV. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Oncology. 2011;25:578\u201386.","journal-title":"Oncology"},{"key":"1371_CR32","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3324\/haematol.2013.100552","volume":"99","author":"NWCJ Van De Donk","year":"2014","unstructured":"Van De Donk NWCJ, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, et al. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica. 2014;99:984\u201396. https:\/\/doi.org\/10.3324\/haematol.2013.100552.","journal-title":"Haematologica"},{"key":"1371_CR33","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","volume":"48","author":"JA Katzmann","year":"2002","unstructured":"Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437\u201344.","journal-title":"Clin Chem"},{"key":"1371_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00732-3","volume":"12","author":"TE Long","year":"2022","unstructured":"Long TE, Indridason OS, Palsson R, Rognvaldsson S, Love TJ, Thorsteinsdottir S, et al. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study. Blood Cancer J. 2022;12:133. https:\/\/doi.org\/10.1038\/s41408-022-00732-3.","journal-title":"Blood Cancer J"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01371-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01371-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01371-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T15:45:19Z","timestamp":1761320719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01371-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1371"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01371-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"13 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.A. has received honoraria from Jonhson & Jonhson. V.G.-C. has received honoraria from Jonhson & Jonhson and Celgene; reports research funding from Jonhson & Jonhson; and received honoraria for consulting and advisory roles for Prothena and Jonhson & Jonhson. B.P. has received honoraria from Jonhson & Jonhson, Amgen, Sanofi, Pfizer, Bristol Myers Squibb\/Celgene and Aptitude Health. C.A. has received honoraria from The Binding Site. B.R.-B. has received a speaker\u2019s fees from Jonhson & Jonhson and Amgen. N.C.G. has received honoraria from Sanofi and Amgen. N.P. has received honoraria for consulting or advisory roles from Amgen, Celgene, Jonhson & Jonhson, Takeda, The Binding Site, GlaxoSmithKline, and Sanofi. M.-V.M. has received honoraria derived from lectures and advisory board activities from Jonhson & Jonhson, Bristol Myers Squibb\/Celgene, Amgen, Takeda, AbbVie, Sanofi, Oncopeptides, Adaptive, Roche, Pfizer, Regeneron, GlaxoSmithKline, Bluebird Bio, and Sea-Gen. For the remaining authors, no relevant conflicts of interest were declared.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics Committee of the University Hospital of Salamanca, with a waiver of informed consent, and conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"179"}}